An astounding 75% of emerging human diseases are of animal origin. Ceva is making a huge contribution in the global fight against brucellosis, avian flu, and other zoonoses such as Q-fever, which recently became a major public health threat in the Netherlands.
According to the World Health Organisation (WHO), 500 000 cases of brucellosis are diagnosed in humans every year. Brucellosis is transmitted from animals to humans mainly by inhaling dust when handling products contaminated by brucella bacteria, or by consuming untreated milk from infected animals.
As an international veterinary pharmaceutical group still actively present in the field of brucellosis control, Ceva is partnering prevention efforts in countries where the pathology is highly endemic. The group offers health authorities a comprehensive vaccination solution, combining the product itself and the technical expertise of one of the leaders in abortive diseases.
At a different level, but perhaps more alarming from a humanitarian point of view, human trypanosomiasis (HAT) threatens millions of people in 36 countries in Sub-Saharan Africa.
In its commitment to One Health, Ceva has made this disease a particular focus and has become a leading supplier of products to control trypanosomiasis as demonstrated through SOS project.
CEVA has developed a vector vaccine, VECTORMUNE HVT-A1 (a recombinant vaccine), making us one of the key players in the worldwide efforts to prevent the spread of avian flu.
It is forecasted that by 2020 there will be a 50% deficit in global protein production. In this context Ceva is committed to finding new solutions to help improve the production of animal protein in all areas of the world.